Omeprazole and warfrin dd interactions
Reading File
Finding Sources
Searching PubMed
omeprazole warfarin drug interaction
Reading File
Reading File
Reading File
Here is a comprehensive summary of the omeprazole–warfarin drug–drug interaction (DDI):
Omeprazole + Warfarin: Drug–Drug Interaction
Mechanism
Omeprazole is a CYP450 inhibitor — specifically, it inhibits CYP2C9, CYP2C19, and CYP3A4, all of which are involved in the hepatic metabolism of warfarin.
- Warfarin exists as two enantiomers: (S)-warfarin (more potent anticoagulant, metabolized mainly by CYP2C9) and (R)-warfarin (metabolized mainly by CYP1A2 and CYP3A4).
- By inhibiting these enzymes — particularly via CYP2C19 competition — omeprazole decreases the clearance of warfarin, causing it to accumulate in plasma.
"Omeprazole is a potent inhibitor of three CYP isozymes involved in warfarin metabolism. When taken with omeprazole, plasma concentrations of warfarin increase, which leads to greater anticoagulant effect and increased risk of bleeding." — Lippincott Illustrated Reviews: Pharmacology
"Omeprazole decreases the clearance of diazepam, warfarin, and clopidogrel owing to competition for the cytochrome P450 isoenzyme CYP2C19." — Sleisenger and Fordtran's Gastrointestinal and Liver Disease
Clinical Consequence
| Effect | Detail |
|---|---|
| ↑ Warfarin plasma levels | Reduced hepatic clearance via CYP inhibition |
| ↑ INR / PT | Enhanced anticoagulation effect |
| ↑ Bleeding risk | Including GI bleeding, bruising, or serious hemorrhage |
Which PPIs Are Most Problematic?
Among all proton pump inhibitors, omeprazole is the most significant CYP inhibitor:
- Only omeprazole (and to a lesser extent esomeprazole) potently inhibits CYP2C19
- Omeprazole also induces CYP1A2, which can add complexity to warfarin's R-enantiomer clearance
- Pantoprazole has the least CYP interaction potential and is preferred when a PPI is needed in patients on warfarin or clopidogrel
"Among the PPIs, only omeprazole inhibits CYP2C19 (thereby decreasing the clearance of disulfiram, phenytoin, and other drugs) and induces the expression of CYP1A2." — Goodman & Gilman's Pharmacological Basis of Therapeutics
Clinical Management
- Monitor INR closely when omeprazole is started, dose-changed, or stopped in patients on warfarin
- Consider switching to pantoprazole (least CYP interaction) if a PPI is clinically needed
- Dose adjustment of warfarin may be necessary — typically a warfarin dose reduction
- Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in stool/urine
Summary Table
| Parameter | Detail |
|---|---|
| Interaction type | Pharmacokinetic (metabolic inhibition) |
| Enzyme involved | CYP2C9, CYP2C19, CYP3A4 |
| Net effect | ↑ warfarin plasma concentration |
| Clinical risk | ↑ INR → bleeding |
| Severity | Moderate–Significant |
| Preferred alternative PPI | Pantoprazole |
Sources: Lippincott Illustrated Reviews: Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Sleisenger and Fordtran's Gastrointestinal and Liver Disease
This is a shared conversation. Sign in to Orris to start your own chat.